Media Features

image

Octane's High Tech Awards - Immunis Chairman, Dr. Hans Keirstead, receives award for "Best Technology Company CEO"

Sep 26, 2024 - The much-anticipated High Tech Awards is a special night celebrating the top entrepreneurs, technology leaders, and innovators in Orange County. We are honored to share that our Chairman, Dr. Hans Keirstead was a winner of the "Best Technology Company CEO." We are thrilled by the recognition and applaud all of the nominees for this incredible achievement.
Watch Here
quadraScope-Logo-150-01-1

quadra Scope - "Immune system restoration to treat obesity and build muscle"

Aug 14, 2024 - Dr. Hans Keirstead is a renowned stem cell expert, serial entrepreneur, and the Chairman of Immunis, a quadraScope portfolio company. quadra Scope interviewed Dr. Keirstead about how Immunis is restoring immune system function with stem cell-derived secretomes to treat chronic inflammation, obesity, and muscle atrophy.
Watch Here
Bloqcube Prix Galien Nominee

Prix Galien USA - 2024 Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"

Aug 13, 2024 - Immunis is honored as a nominee for Prix Galien's "Best Startup." It is remarkable for Immunis to be featured among a list of incredibly innovative and groundbreaking companies. We are humbled by this recognition and excitedly await for the Prix Galien Gala in NYC in November.
Read Here
image

Octane High Tech Awards - Immunis is a Finalist for "Best Technology Company CEO"

Aug 14, 2024 - Octane's 2024 High Tech Awards announced that Immunis' Chairman, Dr. Hans Keirstead, is a finalist for the award for "Best Technology Company CEO."
Read Here
image

Imaging Technology News - "Immunis Partners with Springbok Analytics on MRI-based AI Muscle Analysis Technology"

Jul 25, 2024 - Imaging Technology News highlights Immunis' use of AI-driven programs to analyze Phase 1/2a clinical trial data.
Read Here
maxresdefault

Sapio Podcast - "Stem Cells - Myth vs Reality with Hans Keirstead, PhD"

Jun 18, 2024 - For Episode 88 of the Sapio Podcast, Dr. Buck Joffrey discusses with Immunis Chairman, Dr. Hans Keirstead, the incredibly promising future for human cell-derived secretome therapies. The 1-hour special covers topics from stem cell basics to the potential benefits of secretomes in extending human healthspan, as well as the importance of careful FDA-regulation when creating novel therapies.
Watch Here
channels4_profile

Modern Healthspan - "Rejuvenation With Exosomes & Stem Cell Secretomes"

Jun 14, 2024 - Modern Healthspan highlights four special guest experts on exosomes and the secretome. These amazing scientists and world innovators include Dr. Harold Katcher, Dr. Hans Keirstead, Dr. Paul Robbins and Dr. Ducan Ross. Collectively, they discuss how stem cells can be used in the rejuvenation of human health.
Watch Here
Screenshot 2024-07-31 at 2.41.55 PM

Modern Healthspan - "The Most Promising Rejuvenation Therapy Now In Clinical Trials"

May 15, 2024 - Dr. Keirstead was an invited guest on human health-focused podcast Modern Healthspan (~80K subscribers) to discuss Immunis’ promising investigational secretome therapy, IMM01-STEM, and the company's mission to reverse muscle atrophy.
Watch Here
Longevity.Technology+Logo+Black+Transparent

Longevity.Technology - "Immunis study shows secretome therapy improves metabolism and muscle and reduces fat in aged mice"

Mar 21, 2024 - Immunis’ publication in Aging Cell was highlighted by Longevity.Technology. Publication: https://pubmed.ncbi.nlm.nih.gov/38500398/
Read Here
NBT-logo-red-1024×280

Nature Biotechnology - "After obesity drugs’ success, companies rush to preserve skeletal muscle"

Mar 5, 2024 - Immunis is establishing a lead position in the muscle regeneration sector. In early March, Nature Biotechnology released a news article highlighting Immunis as one of the top companies making advancements towards sarcopenia therapies. The importance in reversing muscle atrophy has recently skyrocketed given the unintended consequence of popular anti-obesity drugs in causing significant muscle loss.
Read Here
image

Irvine Standard - "This Irvine scientist, a trailblazer in stem cell research, hopes to cure cancer – and maybe even old age"

Feb 2024 - The Irvine Standard dedicated a full spread to celebrate Dr. Keirstead’s successful career in regenerative medicine. The City of Irvine recognizes Dr. Keirstead as an incredible trailblazer in stem cell research, highlighting his ongoing efforts to combat age-related diseases and extend human healthspan.
Read Here
4178d0_c94bdf2dab524881adde2b47ec83a855~mv2

Longevity Investors Lunch Panel Discussion - "Unlocking the Secrets of Brain Longevity"

Jan 16, 2024 - This thought-provoking panel was hosted by the Longevity Investors Lunch in Davos, as part of the World Economic Forum. The discussion was moderated by Dr. Hans Keirstead, Chairman of the Board at Immunis. He skillfully guides the conversation on the intricacies of brain longevity with distinguished panel features by Rajiv Ahuja, Associate Director at the Milken Institute Future of Aging and Dr. Emil Kendziorra, Founder and CEO of Tomorrow Biostasis.
Watch Here
pbs_share_twitter.146028bb9726

PBS - "How Stem Cell Therapy Heals Cancer and Immune System"

Jan 2, 2024 - PBS filmed a segment on Dr. Hans Keirstead to discuss his mission of using stem cell therapeutics to address cancer and immune system dysfunction.
Watch Here
Screenshot 2024-08-05 at 10.57.46 AM

Longevity+Desci Summit - "Is Aging Truly Reversible?"

Dec 21, 2023 - Dr. Hans Keirstead, Dr. Oliver Medvedik, Dr. Aubrey de Grey, Dr. Peter Fedichev, and Dr. Hanadie Yousef, debate whether or not aging is truly reversible at the Longevity+DeSci Summit NYC (Ending Age-related Diseases Summit 2023)
Watch Here
Longevity-investment-bulletin-hero-230201-768×512.jpg

Longevity.Technology - "Beyond the secretome: targeting age-related immune decline"

Oct 5, 2023 - Dr. Keirstead was interviewed by Danny Sullivan from Longevity.Technology to discuss how Immunis plans to change the course of aging and immune-related diseases with immunomodulatory secretomes.
Read Here
image

Biotechnology Innovation Organization - I Am Bio Podcast Episode with Chairman Dr. Hans Keirstead

Aug 3, 2023 - Hear what inspires our Chairman, Dr. Hans Keirstead, to develop biomedical innovations that strengthen our immune system. This special episode was filmed by the Biotechnology Innovation Organization for their "I am Bio" video series.
Watch Here
Slide1

Longevity Insider - "The Secretome: A Revolutionary Approach to Age-Related Diseases"

Jun 18, 2023 - Longevity Insider highlights a review by Immunis' Sr. Scientific Communications Manager, Dr. Karissa Jade Muñoz. Dr. Muñoz discusses the history of secretome research, its advantages over traditional stem cell therapies, and its potential in improving human healthspan.
Read Here
bannerx-520×293

ABC New Radio, West Coast Business Review - Interview with Dr. Keirstead

Apr 12, 2023 - Dr. Keirstead was an invited speaker on ABC news radio’s West Coast Business Review Podcast. Host Dr. Bill Morris had Dr. Keirstead delve deep into the mission behind Immunis and the limitless applications of secretomes.
Listen Here
mT3A4zz0fEc8hSMW.jpg-large

NextMed Health - "The Future of Regenerative Longevity - Dr. Hans Keirstead"

Mar 15, 2023 - What is the future of extending human healthspan? In his compelling talk at NextMed Health 2023, stem cell and regenerative medicine pioneer, Dr. Hans Keirstead, discusses how the stem cell 'secretome' can enable immunomodulation to address elements of ageing.
Watch Here
Screenshot 2024-07-31 at 1.22.58 PM

Klick Group - "Navigating Immune Engineering and New Treatment Development"

Mar 15, 2023 - At the NextMed Health Conference, Chairman Dr. Hans Keirstead was interviewed by Dr. Gautam Gulati from Klick Group to share how Immunis is navigating the world of aging and longevity research from an immune perspective.
Watch Here
image

Delveinsight - "KNEE OSTEOARTHRITIS PIPELINE INSIGHT REPORT | 40+ COMPANIES AND 40+ DRUGS"

Jan 16, 2023 - "DelveInsight’s knee osteoarthritis pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for knee osteoarthritis treatment."
Read Here
Lifespan_Press_Logo_2020.png

Lifespan.io - "Immunis Begins Clinical Trial of Stem Cell Secretome"

Jan 5, 2023 - Immunis was highlighted by Lifespan.io, an online scientific news hotspot supported by The Lifespan Extension Advocacy Foundation.
Read Here
quadraScope-Logo-150-01-1

quadraScope - "Targeting the immune system to extend healthspan – interview with Dr. Hans Keirstead"

Dec 14, 2022 - quadraScope's Dr. José Navarro-Betancourt interviews Dr. Hans Keirstead, an internationally known stem cell expert, serial entrepreneur, and Chairman of Immunis, a quadraScope portfolio company aiming to enhance the function of the immune system using human cell-derived secretomes.
Watch Here
image

UCI LiveWell Magazine - "UCI opens clinical trial of stem cell-derived therapy for knee arthritis"

Nov 29, 2022 - UCI published an interview in LiveWell magazine with Dr. Dean Wang, the primary clinical investigator of Immunis’ Phase 1/2a clinical trial. Dr. Wang discusses the revolutionary therapeutic potential of cellular secretomes in ameliorating age-related diseases like muscle atrophy associated with knee osteoarthritis and expresses his enthusiasm for Immunis’ clinical trial.
Read Here
11640844025

Sciinov Healthcare - "A Stem Cell-Derived Secretome Targeting Age-Acquired Immune Decline: Dr. Hans Keirstead"

Nov 1, 2022 - Dr. Hans Keirstead was an invited speaker at the Sciinov Conference, which aims to benefit attendees through networking amongst high-quality health experts. Please enjoy Dr. Keirstead's presentation on the mission of Immunis to reverse age-related diseases using human cell-derived secretomes.
Watch Here
image

Delveinsight - "Rich Insights into the Knee Osteoarthritis Clinical Trial Analysis Featuring 60+ Companies and Therapies"

Oct 31, 2022 - Immunis was recognized as one of the top companies for knee osteoarthritis treatment research by DelveInsight Business Research LLP.
Read Here